Undisclosed second antigen

The term 'Undisclosed second antigen' is a placeholder designation used in pharmaceutical research and development, typically within the context of multi-specific therapeutic agents such as bispecific antibodies, trispecific antibodies, or CAR-T cell therapies (ClinicalTrials.gov). It indicates that while a second target has been identified and is being utilized in a drug's design, its specific identity remains proprietary and has not been publicly revealed by the developer to maintain a competitive advantage. Because this is a generic placeholder rather than a specific biological molecule, it lacks defined biological functions, molecular classifications, or established roles in disease. Analysts frequently encounter this term in early-stage clinical trial registries or corporate pipelines during the pre-clinical and Phase 1 stages of development. Once the drug candidate progresses further in clinical development or patent applications are published, this placeholder is typically replaced with the specific name of the protein or receptor being targeted.

Other names

Undisclosed antigenProprietary targetUndisclosed target

Not applicable